Advertisement

Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm

  • Matteo PicciniEmail author
  • Giuseppe Gaetano Loscocco
  • Giacomo Gianfaldoni
  • Pietro Grieco
  • Giuseppina Palmieri
  • Sofia Pilerci
  • Barbara Scappini
  • Alberto Bosi
Letter to the Editor

Dear Editor,

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and extremely aggressive myeloid malignancy arising from dendritic cell (DC) precursors typically affecting skin and/or bone marrow. Despite excellent complete response (CR) rates with induction chemotherapy, the disease has a marked tendency to relapse and become chemoresistant, with an overall dismal outcome. Frontline treatment with acute myeloid leukemia-like and acute lymphoblastic leukemia-like regimens resulted in disease-free and overall survival advantage, although allogeneic stem cell transplantation appears to be the only therapeutic approach with potential for disease eradication and long-term survivorship [1]. Data on efficacy of specific therapeutic regimens in the relapsed/refractory (R/R) setting are lacking, mainly because of the rarity of this disease entity. Conventional chemotherapy seems to provide only limited and transient clinical benefit [2]. Recently, CD123-directed cytotoxin...

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Sullivan JM, Rizzieri DA (2016) Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology 2016:16–23CrossRefGoogle Scholar
  2. 2.
    Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, De Padova N, Becker PS (2017) Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm. Am J Hematol 92:E75–E77CrossRefGoogle Scholar
  3. 3.
    Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S et al (2019) Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380:1628–1637CrossRefGoogle Scholar
  4. 4.
    Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA (2017 February) Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax. Cancer Discov 7(2):156–164CrossRefGoogle Scholar
  5. 5.
    DiNardo CD, Rausch CR et al (2018) Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol 93:401–407CrossRefGoogle Scholar
  6. 6.
    Loscocco GG, Piccini M, Vergoni F, Vannucchi AM, Bosi A (2018 Nov) A case of disseminated blastic plasmocytoid dendritic cell neoplasm. Am J Hematol 93(11):1433–1434CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Azienda Ospedaliera Universitaria CareggiFirenzeItaly

Personalised recommendations